Purchase Order 36C26122P0417

Award Date 1/6/22
Potential Completion Date 9/30/22
Potential Value $81K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Palo Alto, CA 94304, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) awarded a $81,342.18 firm fixed-price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical TYVASO. The contract, which does not have a set-aside designation, is to support the VA's Veterans Integrated Service Network 21 (VISN 21) and has an ultimate completion date of September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and...
This is a $81,632.25 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit subsidiary of Express Scripts that specializes in providing specialty pharmaceutical services. The contract is for the delivery of the medication Tyvaso, which is used to treat pulmonary arterial hypertension. The contract has no set-aside designation and was awarded on April 6, 2021, with a completion date of September 30, 2021....
This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract, valued at $94,899.21, is for the delivery of the drug Tyvaso, which is used to treat pulmonary arterial hypertension. The contract is not associated with a larger contract vehicle and does not have a set-aside designation. Accredo Health Group, Inc. is the prime contractor and there are no major...
This is a $93,341.96 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the specialty pharmaceutical Tyvaso, which is used to treat pulmonary arterial hypertension. This contract is part of Accredo Health Group's ongoing work supporting the VA's Veterans Integrated Service Network (VISN) 21 with the distribution of specialty medications. The...
This is a firm fixed-price purchase order awarded by the Veterans Integrated Service Network 19 (VISN 19) of the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the express delivery of second quarter pharmacy orders with a ceiling value of $86,938.57 and a completion date of July 24, 2017. Accredo Health Group, Inc. is a key distributor of complex and high-value medications, primarily serving the...
This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company that specializes in specialty pharmaceutical services. The contract, valued at $75,576.09, is for the delivery of Uptravi medicine to support the VA's Veterans Integrated Service Network (VISN) 6. The contract does not have a set-aside designation and was awarded on October 27, 2020, with a completion date of...
This is a $103,003.20 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The contract is for the delivery of various complex and high-value medications, primarily to support the VA's Veterans Integrated Service Network (VISN) healthcare facilities. Key medications provided under this contract include drugs used to treat...
This is a $40,697.68 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the supply of specialty pharmaceutical products, including medications to treat pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders. The contract has an ultimate completion date of March 14, 2025 and is part of the VA's Veterans...
This is a federal contract award to Accredo Health Group, Inc., a prime contractor, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 21. The award is for the specialty medication UPTRAVI, with a potential value of $104,778.03 and a completion date of September 30, 2021. The contract is a firm fixed price purchase order with no set-aside designation. Accredo Health Group, a for-profit organization, provides specialty pharmacy...
This federal contract award to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, was made by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) for the delivery of specialty pharmaceutical products. The contract, valued at $138,543.43, is a firm fixed price purchase order without any set-aside designation. Accredo, as the prime contractor, provides specialty medications directly to VA medical centers and facilities across the country to...

This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs' Veterans Integrated Service Network 21 to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, for the delivery of the specialty pharmaceutical Tyvaso. The total ceiling value of the contract is $81,342.18, with a period of performance through September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and high-value medications, primarily serving the healthcare needs of veterans through the VA. This contract award is not associated with a larger contract vehicle and does not have a set-aside designation.

Generated 4/3/25, 1:08 AM